Nasal antivirals created by researchers on Columbia University Vaglos College of Physicians and Surgeons blocked the transmission SARS-CoV-2 In ferrets, prescribing nasal sprays can also prevent infection in people exposed to the new coronavirus.
The combination of the spray in Moscow, MD and Matteo Poroto, PhD, a lipop ti pied spray developed by iat Moscow, is the director of the Center for Host-Pathogen Interaction and is designed to prevent new coronavirus from entering host cells.
Antiviral lipopeptides are inexpensive to produce, have a long shelf life, and do not require refrigeration. These features set it apart from other antiviral approaches under development, including monoclonal antibodies. The new nasal lipopeptide may be ideal for preventing the spread of COVID in the United States and globally; Transportable and stable compounds can be key, especially in rural, low-income and hard-to-reach populations.
The printout of the study came bioRxiv On November 5, 2020; The first compound of the compound and a paper describing its effect in the 3D model of the human lung were first published in the journal mBio On October 20, 2020. In this model of the human lung, the compound was able to extinguish the initial infection, prevent the spread of the virus inside the lungs, and there is no toxicity in the airway cells.
Ferretts a model for respiratory diseases
Ferrates are frequently used in the study of respiratory diseases because the lungs of these animals and humans are similar. Ferrets are highly susceptible to infection with SARS-Co-2, and the virus spreads easily from ferrite to ferrite.
Anne Moscow and Matteo Porto. Credit: Photo of the Center for Host-Pathogen Interaction, Columbia University Department of Pediatrics.
In this study, 100% of untreated ferrets were infected by their virus-shedding cagemates, such as arranging beds for people or conditions close to subsistence.
Moscow and Poroto have previously developed similar lipopeptides – small proteins attached to cholesterol or tocopherol molecules to prevent infection of cells by other viruses, including measles, parainfluenza and Nipah virus. These anti-viral compounds have been largely challenging to bring to human testing, as they prevent infections that are most prevalent or severe in terms of low income.
When SARS-Cavi-2 emerged earlier this year, researchers adapted their designs to the new coronavirus. Moscow and Poroto say, “The lesson we want to emphasize is the importance of using basic science to treat viruses that affect the human population globally.” The results of our previous research led to the rapid use of our methods. COVID-19”
Lipopeptides prevent the virus from infecting cells
Lipopeptides prevent the virus from fusing with its host cell membrane, an essential step that envelops viruses, including SARS-CoV-2, infecting cells. To fuse, the new coronavirus flies before its spike protein contracts into a compact bundle that drives the fusion.
The compound formed by Moscow and Porotto identifies the SARS-Co-2 spike, attaches itself to the exposed region, and prevents the spike protein from adopting the compact shape required for fusion.
In ferrite experiments, lipoptides are delivered to the nose of six ferrets. Pairs of treated ferrets were then placed with two control ferrets that were infected with saline nasal spray and one ferrate SARS-Covi-2.
After 24 hours of direct contact between the ferrets, tests revealed that none of the treated ferrets were able to catch the virus from their infected cagemates and their viral load was definitely zero, while all the animals in control were highly infected.
Lipopeptides are easily administered
Moscow and Poroto suggest that these peptides can be used in any situation where an inadvisable person is exposed, whether at home, school, health care or in the community.
“Even in the ideal scenario with the majority of the population being vaccinated – and with full confidence and adherence to vaccination procedures – these antivirals will become an important complement to protecting individuals and controlling infections,” says Moscow and Poroto. People who cannot be vaccinated or have not developed an immune system will especially benefit from the spray.
Antivirals are easily administered and based on the experience of scientists with other respiratory viruses, protection will be immediate and last at least 24 hours.
Scientists hope to rapidly advance a preventive approach to human trials with the goal of having transmission during this epidemic.
Reference:
“Intranasal fusion inhibition lipopeptide inhibits direct contact SARS-Cavi-2 ferrites transmission” Rory D. De Verez, Catherine S. Smitz, Francesca T. Bovier, Danny Knock, Bart L. By Hagmanus, Sudipta Biswas, Barry Rocks, Samuel H. Gellman, Christopher a. Alabi, Rick L. De Swart, N. Moscow and Matteo Porto, 5 November 2020, bioRxiv.
DOI: 10.1101 / 2020.11.04.361154
“Coronavirus entry prohibited In vitro And Former Vivo Wipter K. Outlaw, Francesca t. Bouvier, Megan c. Myers, Maria Ann. Kejimet, Yun Xu, Michelle J. Lynn, by Amin Addatia via a lipid-conjugated peptide obtained from the SARS-COV-2 spike glycoprotein HRC domain. , Nicole AP Lieberman, Vikas Peddu, Zupping Zee, Pei-Yong Shi, Alexander L. Greninger, Samuel H. Gelman, Dennis A. Bente, Mos’s Moscow, Mateo Porto, 20 October October 2020,mBio.
DOI: 10.1128 / MBO.01935-20
Annie Moscow, MD, Sherry L. Morrison is Professor of Immunology (in Microbiology and Immunology), Professor of Pediatrics, and Professor of Physiology and Cellular Biophysics at Columbia University’s Vegalos College of Physicians and Surgeons.
Matteo Porotto, PhD, is an associate professor of viral molecular pathogenesis in the Department of Pediatrics at Columbia University Vagellos College of Physicians and Surgeons.
Other authors: Rory D. De Verez (Erasmus University Medical Center, Netherlands), Catherine S. Smitz (Erasmus), Francesca T. Bovier (Columbia University Irving Medical Center and University of Campania “Luigi Vanvitelli”, Italy), Danny Knock (Erasmus), Bart L. Hagmanus (Erasmus), Sudipta Biswas (Cornell University), Barry Rocks (Erasmus), Samuel H. Gelman (University of Wisconsin, Madison), Christopher A. Alabi (Cornell), and Rick L. D. Swart (Erasmus).
The work was awarded by the National Institutes of Health (AI146980, AI121349, NS091263, and AI114736), the Sharon Golab Fund of Columbia University Irving Medical Center, the Columbia Children’s Health COVID-19 Award, and the Harrington Discovery Institute COVID. 19 awards.
Mos’s Moscow, Matteo Porotto, Rory de Verez, Francesca Bouvier, and Rick de Swart are listed as researchers on the Provisional Patent Application Covering Findings reported in this article.
